Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants

[1]  Yunqian Pan,et al.  FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants , 2013, The Prostate.

[2]  N. Yoo,et al.  Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers , 2013, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[3]  D. Tindall,et al.  Posttranslational Modification of the Androgen Receptor in Prostate Cancer , 2013, International journal of molecular sciences.

[4]  Jindan Yu,et al.  BRCA1 is a negative modulator of the PRC2 complex , 2013, The EMBO journal.

[5]  M. Rubin,et al.  Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover , 2013, Proceedings of the National Academy of Sciences.

[6]  D. Bowtell,et al.  The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. , 2013, Cancer cell.

[7]  K. Silverstein,et al.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. , 2013, Cancer research.

[8]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[9]  P. Nelson,et al.  Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. , 2012, Cancer research.

[10]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[11]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[12]  P. Nelson,et al.  Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. , 2011, Cancer research.

[13]  D. Tindall,et al.  Alternatively spliced androgen receptor variants. , 2011, Endocrine-related cancer.

[14]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[15]  P. Stattin,et al.  Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival , 2011, PloS one.

[16]  B. O’Malley,et al.  Tumor Suppressor Role for the SPOP Ubiquitin Ligase in Signal-Dependent Proteolysis of the Oncogenic Coactivator SRC-3/AIB1 , 2011, Oncogene.

[17]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[18]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[19]  Lu Gan,et al.  Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2 , 2010, Nature Cell Biology.

[20]  Jonathan W. Pillow,et al.  POSTER PRESENTATION Open Access , 2013 .

[21]  N. Socci,et al.  Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010, Proceedings of the National Academy of Sciences.

[22]  P. Nelson,et al.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.

[23]  J Wade Harper,et al.  Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. , 2009, Molecular cell.

[24]  Zhiyong Guo,et al.  Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. , 2009, Cancer cell.

[25]  Zhiyong Guo,et al.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.

[26]  Christopher D. Brown,et al.  Analysis of Drosophila Segmentation Network Identifies a JNK Pathway Factor Overexpressed in Kidney Cancer , 2009, Science.

[27]  Haojie Huang,et al.  A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. , 2008, Cancer research.

[28]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[29]  D. Tindall,et al.  CDK2-Dependent Phosphorylation of FOXO1 as an Apoptotic Response to DNA Damage , 2006, Science.

[30]  C. Chien,et al.  A hedgehog-induced BTB protein modulates hedgehog signaling by degrading Ci/Gli transcription factor. , 2006, Developmental cell.

[31]  S. H. Baek,et al.  BTB Domain-containing Speckle-type POZ Protein (SPOP) Serves as an Adaptor of Daxx for Ubiquitination by Cul3-based Ubiquitin Ligase* , 2006, Journal of Biological Chemistry.

[32]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[33]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Ittmann,et al.  SRC-3 is required for prostate cancer cell proliferation and survival. , 2005, Cancer research.

[35]  Dmitri A. Nusinow,et al.  Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Tindall,et al.  Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Dieterle,et al.  Arabidopsis AtCUL3a and AtCUL3b Form Complexes with Members of the BTB/POZ-MATH Protein Family1 , 2005, Plant Physiology.

[38]  E. Wilson,et al.  An Androgen Receptor NH2-terminal Conserved Motif Interacts with the COOH Terminus of the Hsp70-interacting Protein (CHIP)* , 2004, Journal of Biological Chemistry.

[39]  Chawnshang Chang,et al.  Phosphorylation‐dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase , 2002, The EMBO journal.

[40]  D. Tindall,et al.  Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. , 2002, Cancer research.

[41]  D. Tindall,et al.  Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.

[42]  D. Tindall,et al.  Identification and characterization of a suppressor element in the 5'-flanking region of the mouse androgen receptor gene. , 1994, Nucleic acids research.

[43]  Jean D. Wilson,et al.  Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells , 1991, Molecular and Cellular Endocrinology.

[44]  R. Vessella,et al.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.

[45]  A. Chinnaiyan,et al.  Recurrent gene fusions in prostate cancer , 2008, Nature Reviews Cancer.

[46]  Raymond J. Deshaies,et al.  Function and regulation of cullin–RING ubiquitin ligases , 2005, Nature Reviews Molecular Cell Biology.

[47]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.